REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Baum, Alina, Ajithdoss, Dharani, Copin, Richard, Zhou, Anbo, Lanza, Kathryn, Negron, Nicole, Ni, Min, Wei, Yi +28 more·2020·Science
DOI 10.1126/science.abe2402

Cited by (524)

Items 301–400 of 524

  1. Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System
    Yunjiao He, Jing Tao Qu, Lan Wei, Shumin Liao, Nianzhen Zheng, Yingzi Liu, Xingyun Wang, Yue Jing, Clifton Kwang-Fu Shen, Chong Ji et al. · 2021 · Frontiers in Immunology
  2. Isolation of a human SARS-CoV-2 neutralizing antibody from a synthetic phage library and its conversion to fluorescent biosensors
    Haimei Li, Bo Zhu, Baowei Li, Li-Mei Chen, Xuerao Ning, Hang Ying Dong, Jingru Liang, Xueying Yang, Jinhua Dong, Hiroshi Ueda · 2022 · Scientific Reports
  3. COVID-19 signalome: Potential therapeutic interventions
    Kenneth H. Lundstrom, Altijana Hromić‐Jahjefendić, Esma Bilajac, Alaa A. A. Aljabali, Katarina Baralić, Nagwa A. Sabri, Eslam Mansour Shehata, Mohamed Raslan, Sara Ahmed Raslan, Ana Cláudia Barbosa Honório Ferreira et al. · 2022 · Cellular Signalling
  4. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
    Ping Ren, Yingxia Hu, Lei Peng, Luojia Yang, Kazushi Suzuki, Zhenhao Fang, Meizhu Bai, Liqun Zhou, Yanzhi Feng, Yongji Zou et al. · 2023 · Signal Transduction and Targeted Therapy
  5. Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants
    Scott A. Hollingsworth, Cameron L. Noland, Karin Vroom, Anasuya Saha, Miranda Sam, Qinshan Gao, Haihong Zhou, David U. Grandy, Sujata Singh, Zhiyun Wen et al. · 2023 · Scientific Reports
  6. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2
    Kuan-Ying Arthur Huang, Daming Zhou, Tiong Kit Tan, Charles Chen, Helen M. E. Duyvesteyn, Yuguang Zhao, Helen Mary Ginn, Ling Qin, Pramila Rijal, Lisa M. Schimanski et al. · 2021 · Theranostics
  7. SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease
    Steven G. Kelsen, Alan S. Braverman, Mark O. Aksoy, Jacob A. Hayman, Puja S. Patel, Charu Rajput, Huaqing Zhao, Susan Gross Fisher, Michael R. Ruggieri, Nina Gentile · 2022 · JCI Insight
  8. Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma
    Ding Yu, Yufeng Li, Hong Liang, Junzheng Wu, Yong Hu, Yan Peng, Taojing Li, Jiawang Hou, Wei-Jing Huang, Li-Dong Guan et al. · 2022 · Advancement of science
  9. Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents
    Monika A. Murillo, Christine M Lomiguen, Mark Terrell, Ashley King, James S. Lin, Silvia Ferretti · 2022 · Aging and Disease
  10. De Novo Design of Anti-COVID Drugs Using Machine Learning-Based Equivariant Diffusion Model Targeting the Spike Protein
    Vidya Niranjan, Akshay Uttarkar, Ananya Ramakrishnan, Anagha Muralidharan, Abhay Shashidhara, Anushri Acharya, Avila Tarani, Jitendra Kumar · 2023 · Current Issues in Molecular Biology
  11. Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines
    Yixiang Deng, C. Atyeo, D. Yuan, T. Chicz, T. Tibbitts, M. Gorman, Sabian Taylor, V. Lecouturier, D. Lauffenburger, R. Chicz et al. · 2023 · Cell Reports
  12. Preclinical animal models to evaluate therapeutic antiviral antibodies.
    Amse De Meyer, P. Meuleman · 2024 · Antiviral Research
  13. COVID-19 antibody development fueled by HIV-1 bNAb research
    Pilar Mendoza, Julio C. C. Lorenzi, C. Gaebler · 2020 · Current Opinion in HIV and AIDS
  14. Early Experience With Neutralizing Monoclonal Antibody Therapy for COVID-19: Retrospective Cohort Survival Analysis and Descriptive Study
    Mark Paul Jarrett, Warren Licht, Kevin R. Bock, Zenobia J. Brown, Jamie S. Hirsch, Kevin Coppa, Rajdeep Brar, Stephen Bello, Ira S. Nash · 2021 · JMIRx Med
  15. Benefits And Risks Of Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19)
    Bradley Brobst, Judith Borger · 2021 · StatPearls
  16. Animal models for studying coronavirus infections and developing antiviral agents and vaccines
    Q. Lin, Chunni Lu, Yuqi Hong, Run-Feng Li, Jin-Ding Chen, Weisan Chen, Jian-Xin Chen · 2022 · Antiviral Research
  17. Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients
    Lili Li, Meiling Gao, Jie Li, Shulong Zu, Yanan Wang, Chunfeng Chen, Dingyi Wan, Jing Duan, Roghiyh Aliyari, Jingfeng Wang et al. · 2021 · Small Methods
  18. Using in vivo animal models for studying SARS-CoV-2
    Camila Braz Pereira da Costa, Ana Claudia de Menezes Cruz, Julio Cesar Queiroz Penha, Helena Carla Castro, Luís Eduardo Ribeiro da Cunha, Norman Arthur Ratcliffe, Rafael Cisne, Francislene Juliana Martins · 2021 · Expert Opinion on Drug Discovery
  19. In Vivo Hematopoietic Stem Cell Gene Therapy for SARS-CoV2 Infection Using a Decoy Receptor
    Hongjie Wang, Chang Long Li, Adebimpe O. Obadan, Hannah Frizzell, Tien-Ying Hsiang, Sucheol Gil, Audrey Germond, Connie Fountain, Audrey E. Baldessari, Steve R. Roffler et al. · 2022 · Human Gene Therapy
  20. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection
    Guidenn Sulbarán, Pauline Maisonnasse, Axelle Amen, Grégory Effantin, Delphine Guilligay, Nathalie Dereuddre‐Bosquet, Judith A. Burger, Meliawati Poniman, Marloes Grobben, Marlyse Buisson et al. · 2022 · Cell Reports Medicine
  21. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants
    Hyeseong Cho, K. K. Gonzales-Wartz, De-Li Huang, M. Yuan, M. Peterson, Janie Y. Liang, N. Beutler, J. Torres, Yu Cong, E. Postnikova et al. · 2021 · bioRxiv
  22. Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine
    Charles C. Reed, Katherine Schultheis, Viviane M. Andrade, Richa Kalia, Jared Tur, Blake Schouest, Dustin Elwood, Jewell N. Walters, Igor Maricic, Arthur Doan et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  23. REGEN-COV protects against viral escape in preclinical and human studies
    Richard Copin, Alina Baum, Elzbieta H Wloga, Kristen E. Pascal, Stephanie Giordano, Benjamin O. Fulton, Anbo Zhou, Nicole Negron, Kathryn Lanza, Newton Chan et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  24. High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination
    Yesseinia Angleró-Rodríguez, Florian A. Lempp, Megha P. Subramanian, James McIninch, Mark K. Schlegel, Dana Bohan, Emily Y. M. Wong, Christopher R. Brown, Donald J. Foster, Adam B. Castoreno et al. · 2024 · Nucleic Acids Research
  25. The COVID‐19 Menace
    Piotr Walczak, Mirosław Janowski · 2021 · Global Challenges
  26. Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine
    Alberto Grandi, Michele Tomasi, Irfan Ullah, Cinzia Bertelli, Teresa Vanzo, Silvia Accordini, Assunta Gagliardi, Ilaria Zanella, Mattia Benedet, Riccardo Corbellari et al. · 2023 · Vaccines
  27. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant
    Liuhai Zheng, Huifang Wang, Xueyan Liu, Chengchao Xu, Mingxiong Tian, Guangwei Shi, Chongzhi Bai, Zhijie Li, Jigang Wang, Shuwen Liu · 2024 · Journal of Medical Virology
  28. Antibodies, epicenter of SARS-CoV-2 immunology
    Simone Pecetta, Mariagrazia Pizza, Claudia Sala, Emanuele Andreano, Piero Pileri, Marco Troisi, Elisa Pantano, Noemi Manganaro, Rino Rappuoli · 2021 · Cell Death and Differentiation
  29. Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19.
    Jie Su, Hong-Zhou Lu · 2021 · BioScience Trends
  30. Real world utilization of REGEN-COV2 at a community hospital
    Jordan Ash, Rachael Leavitt, Tyson Dietrich, Sarah Schritter, James A. Wells, Anthony Santarelli, John V. Ashurst · 2021 · The American Journal of Emergency Medicine
  31. In vitro high-content tissue models to address precision medicine challenges
    Samson Afewerki, Thiago Domingues Stocco, André D. R. Silva, André Sales Aguiar Furtado, Gustavo Fernandes de Sousa, Guillermo U. Ruiz‐Esparza, Thomas Jay Webster, Fernanda Roberta Marciano, Maria Strømme, Yu Shrike Zhang et al. · 2022 · Molecular Aspects of Medicine
  32. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection
    Mengjia Lu, Weitong Yao, Yujun Li, Danting Ma, Zhaoyong Zhang, Haimin Wang, Xiaojuan Tang, Yanqun Wang, Chao Li, Dechun Cheng et al. · 2023 · Microbiology Spectrum
  33. The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients
    Megan McAleavy, Qian Zhang, Peter J. Ehmann, Jianing Xu, Matthew F. Wipperman, Dharani K. Ajithdoss, Pan Li, Matthew Wakai, Raphael Simonson, Abhilash Gadi et al. · 2021 · Molecular and Cellular Biology
  34. A mixture of essential oils from three Cretan Aromatic Plants (thyme, Greek sage and Cretan dittany, CAPeo) inhibits SASR-CoV-2 proliferation: in vitro evidence and a Proof-of-Concept intervention study in mild ambulatory COVID-19-positive patients
    Christos D Lionis, Ioannis Karakasiliοtis, Elena Petelos, Manolis Linardakis, Athanasios Diamantakis, Emmanouil K. Symvoulakis, Maria I. Panopoulou, Marilena Kampa, Stergios Pirintsos, George Sourvinos et al. · 2021 · medRxiv
  35. SARS-CoV-2 hijacks neutralizing dimeric IgA for enhanced nasal infection and injury
    Biao Zhou, Runhong Zhou, Jasper Fuk‐Woo Chan, Jianwei Zeng, Qi Zhang, Shuofeng Yuan, Li Liu, Rémy Robinot, Sisi Shan, Jiwan Ge et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  36. Inhalable dry powders of a monoclonal antibody against SARS-CoV-2 virus made by thin-film freeze-drying
    Haiyue Xu, Sawittree Sahakijpijarn, Chaeho Moon, Christopher J. Emig, Marco A. Mena, Steven J. Henry, Adela A. Vitug, Christian John Ventura, Philip J. Kuehl, David Revelli et al. · 2024 · International Journal of Pharmaceutics
  37. A bacteriophage-based virus-like particle vaccine induces cross-reactive neutralising antibodies against porcine epidemic diarrhoea viruses (PEDV)
    Jixiang Gu, Xu Zheng, Chunhui Li, Shipeng Wang, Xiangyu Xie, Martin F. Bachmann, Yuchen Nan, Liang Li, Sun Pei, Lisha Zha et al. · 2025 · Veterinary Research
  38. Standardized Two-Step Testing of Antibody Activity in COVID-19 Convalescent Plasma
    Pavlo Gilchuk, Isaac P. Thomsen, Sandra M. Yoder, Eric J. Brady, James D. Chappell, Laura J. Stevens, Mark R. Denison, Rachel E. Sutton, Rita E. Chen, Laura A. VanBlargan et al. · 2021 · iScience
  39. Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails
    Hang Ma, Huifang Zong, Junjun Liu, Yali Yue, Yong Ke, Yunji Liao, Haoneng Tang, Lei Wang, Shusheng Wang, Yunsheng Yuan et al. · 2023 · Acta Pharmacologica Sinica
  40. Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants
    Hangtian Guo, Yixuan Yang, Tiantian Zhao, Yuchi Lu, Yan Gao, Tinghan Li, Hang Xiao, Xiaoyu Chu, Le Zheng, Wanting Li et al. · 2023 · Communications Biology
  41. Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA
    Daniel O. Griffin, Chace McNeil, James Okusa, Diana Berrent, Yinglong Guo, Sarah E. Daugherty · 2023 · BMJ Open
  42. Dalbavancin: novel candidate for COVID-19 treatment
    Markus Hoffmann, Yeonhwa Jin, Stefan Pöhlmann · 2021 · Cell Research
  43. Current state-of-the-art and potential future therapeutic drugs against COVID-19
    Ailong Sha, Yi Liu, Haiyan Hao · 2023 · Frontiers in Cell and Developmental Biology
  44. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects
    Madeleine F. Jennewein, Anna J. MacCamy, Nicholas R. Akins, Junli Feng, Leah J. Homad, Nicholas K. Hurlburt, Emily Seydoux, Yu-Hsin Wan, Andrew B. Stuart, Venkata Viswanadh Edara et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  45. AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo
    Christopher J. Emig, Marco A. Mena, Steven J. Henry, Adela A. Vitug, Christian John Ventura, Douglas Fox, Xammy Huu Nguyenla, Haiyue Xu, Chaeho Moon, Sawittree Sahakijjpijarn et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  46. Rapid protein evolution by few-shot learning with a protein language model
    Kai-Yi Jiang, Zhao-Qing Yan, Matteo Di Bernardo, Samantha R. Sgrizzi, Lukas Villiger, Alisan Kayabolen, Byungji Kim, Josephine K. Carscadden, M. Hiraizumi, Hiroshi Nishimasu et al. · 2024 · bioRxiv
  47. Predicting the presence of infectious virus from PCR data: A meta-analysis of SARS-CoV-2 in non-human primates
    Celine E. Snedden, J. Lloyd-Smith · 2024 · PLoS Pathogens
  48. Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection
    Rui Qiao, Jiayan Li, Jiami Gong, Yuchen Shao, Jizhen Yu, Yumeng Chen, Yinying Lu, Luxuan Yang, Luanfeng Lin, Zixin Hu et al. · 2025 · Vaccines
  49. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection
    Pragya Dhruv Yadav, Sanjeev Kumar Mendiratta, Sreelekshmy Mohandas, Arun Kumar Singh, Priya Abraham, Anita Shete, Sanjay Bandyopadhyay, Sanjay Kumar, Aashini Parikh, Pankaj Kalita et al. · 2021 · Viruses
  50. Feasibility Studies of Nebulized SARS-CoV-2 Neutralizing Antibody in Mice and Cynomolgus Monkeys
    Jilei Jia, Zhaojuan Yin, Xiao Zhang, Huimin Li, Dan Meng, Qianqian Liu, Hongfang Wang, Meng Han, Shixiang Suo, Yan Liu et al. · 2022 · Pharmaceutical Research
  51. Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening
    Xiaopeng Hu, Jiahua Cui, Jun Chen, Shujuan Du, Xinyu Wang, Yabin Zhang, Jiajun Qian, Haifeng Chen, Wei Fang, Qiliang Cai et al. · 2022 · Virus Research
  52. Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research
    Sachithra Gunasekara, Miruthula Tamil Selvan, Craig A. Miller, Jennifer M. Rudd · 2022 · International Journal of Translational Medicine
  53. A systems biology approach to define SARS-CoV-2 correlates of protection
    Caolann Brady, Tom Tipton, Oliver T. Carnell, Stéphanie Longet, Karen E. Gooch, Yper Hall, Javier Salguero, Adriana Tomić, Miles W. Carroll · 2025 · npj Vaccines
  54. Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
    Hong‐Yi Zheng, 中国科学院昆明动物研究所遗传资源与进化国家重点实验室, 生物安全大科学中心, 中国科学院昆明动物研究所-香港中文大学生物资源与疾病分子机理联合实验室, 云南 昆明 650223, 中国, Tian‐Zhang Song, Yong‐Tang Zheng, 中国科学院昆明动物研究所模式动物表型与遗传研究国家重大科技基础设施(灵长类设施), 国家非人灵长类实验动物资源库, 云南 昆明 650107, 中国 · 2024 · 动物学研究
  55. Whole-body visualization of SARS-CoV-2 biodistribution in vivo by immunoPET imaging in non-human primates
    Alexandra Detrille, Steve Huvelle, Marit J. van Gils, Tatiana Geara, Quentin Pascal, Jonne L. Snitselaar, Laëtitia Bossevot, Mariangela Cavarelli, Nathalie Dereuddre‐Bosquet, Francis Relouzat et al. · 2025 · Nature Communications
  56. T Cell Responses Correlate with Self-Reported Disease Severity and Neutralizing Antibody Responses Predict Protection against SARS-CoV-2 Breakthrough Infection
    Zhen Zhao, Attila Kumánovics, Tanzy Love, Stacy E.F. Melanson, Qing H. Meng, Alan H.B. Wu, Joesph R Wiencek, Fred S. Apple, Caitlin R. Ondracek, David D. Koch et al. · 2023 · Viruses
  57. High-throughput screening of mutations affecting SARS-CoV-2 spike functions
    Shuai Xia, Zezhong Liu, Shibo Jiang · 2023 · Trends in Immunology
  58. SARS‐CoV‐2 Omicron (B.1.1.529) infection in rhesus macaques, hamsters, and BALB/c mice with severe lung histopathological damage
    Wenhai Yu, Junbin Wang, Yun Yang, Cong Tang, Chengyun Yang, Bai Li, Haixuan Wang, Yanan Zhou, Qing Mei Huang, Hao Yu Yang et al. · 2023 · Journal of Medical Virology
  59. Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19
    Andrey L. Matveev, Oleg V. Pyankov, Yana A. Khlusevich, Olga V Tyazhelkova, Lyudmila A. Emelyanova, Anna M. Timofeeva, Andrey V. Shipovalov, Чечушков Антон Владимирович, Natalia Zaitseva, Gleb A. Kudrov et al. · 2023 · International Journal of Molecular Sciences
  60. Passive Immunity Should and Will Work for COVID-19 for Some Patients
    Nevio Cimolai · 2021 · Clinical Hematology International
  61. Animal Models of COVID-19: Nonhuman Primates
    Dhiraj Kumar Singh, Journey Cole, Ruby A. Escobedo, Kendra J. Alfson, Bindu Singh, Tae‐Hyung Lee, Xavier A. Alvarez, Shashank Ganatra, Ricardo Carrion, Deepak Kaushal · 2022 · Methods in molecular biology
  62. Delta variant: Partially sensitive to vaccination, but still worth global attention
    Meng Zhang, Yan-Chao He, Zhijun Jie · 2022 · Journal of Translational Internal Medicine
  63. Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors
    Ling Ma, Yali Li, Ting Shi, Zhiling Zhu, Jian‐Yuan Zhao, Yongli Xie, Jiajia Wen, Saisai Guo, Jing Wang, Jiwei Ding et al. · 2023 · Biomedicine & Pharmacotherapy
  64. Pre-clinical models to define correlates of protection for SARS-CoV-2
    Caolann Brady, Tom Tipton, Stéphanie Longet, Miles W. Carroll · 2023 · Frontiers in Immunology
  65. Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies
    N. Khullar, Jasvinder Singh Bhatti, Satwinder Singh, Bhawana Thukral, P. Reddy, G. K. Bhatti · 2023 · World Journal of Gastroenterology
  66. Evolution of SARS-CoV-2 Spikes shapes their binding affinities to animal ACE2 orthologs
    Weitong Yao, Yujun Li, Danting Ma, Xu-Dong Hou, Haimin Wang, Xiaojuan Tang, Dechun Cheng, He Zhang, Chengzhi Du, Hong Pan et al. · 2023 · Microbiology Spectrum
  67. Function and mechanism of bispecific antibodies targeting SARS-CoV-2
    Zhaohui Li, Zengyuan Zhang, Steven T. Rosen, Mingye Feng · 2024 · Cell Insight
  68. Immune titers of protection against severe acute respiratory syndrome coronavirus 2: are we there yet?
    Yoanna Slabakova, Dilyana Gerenska, Nedelcho Ivanov, Tsvetelina Veselinova Velikova · 2022 · Exploration of Immunology
  69. Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
    Xiaohui Wei, Na Rong, Jiangning Liu · 2022 · Frontiers in Immunology
  70. Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
    Aruni Jha, Douglas Barker, Jocelyne M. Lew, Vinoth K. Manoharan, Jill van Kessel, Robert E. Haupt, Derek Toth, Matthew B. Frieman, Darryl Falzarano, Shantha Kodihalli · 2022 · Scientific Reports
  71. Intranasal SARS-CoV-2 spike-based immunisation adjuvanted with polyethyleneimine elicits mucosal and systemic humoral responses in mice
    Lachlan Paul Deimel, Xin Liu, Javier Gilbert‐Jaramillo, Sai Liu, William James, Quentin James Sattentau · 2022 · Journal of Immunological Methods
  72. Identification of anti-SARS-CoV-2 agents based on flavor/fragrance compositions that inhibit the interaction between the virus receptor binding domain and human angiotensin converting enzyme 2
    Yasumitsu Nishimura, Kenta Nomiyama, Shuichiro Okamoto, Mika Igarashi, Yusuke Yorifuji, Yukino Sato, Ayasa Kamezaki, Aya Morihara, Futoshi Kuribayashi, 明 山内 · 2022 · PLoS ONE
  73. Efficacy of Plant-Made Human Recombinant ACE2 against COVID-19 in a Golden Syrian Hamster Model
    Choon‐Mee Kim, Dong‐Min Kim, Mi-Seon Bang, Jun-Won Seo, Da‐Young Kim, Na Ra Yun, Sung‐Chul Lim, Ju Hyung Lee, Eun‐Ju Sohn, Hyangju Kang et al. · 2023 · Viruses
  74. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles
    Dateng Li, Meng Xu, Andrea T. Hooper, Diana Rofail, Kusha A Mohammadi, Yiziying Chen, Shazia Ali, Thomas D. Norton, David M. Weinreich, Bret J. Musser et al. · 2023 · Scientific Reports
  75. Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant
    Hui Sun, Yizhen Wang, Xiuting Chen, Yanan Jiang, Siling Wang, Yang Huang, Liqin Liu, Li Yu, Miaolin Lan, Huilin Guo et al. · 2023 · Journal of Virology
  76. Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread
    Himanshu Ajmera, Sudarshan Singh Lakhawat, Naveen Malik, Akhılesh Kumar, Jasvinder Singh Bhatti, Vikram Kumar, Himanshu Gogoi, Sunil Kumar Jaswal, Sanjeev Chandel, Pushpender Kumar Sharma · 2024 · Current Protein and Peptide Science
  77. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall
    Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Giulia de Luca, Massimo Franchini, Daniele Focosi · 2022 · Expert Opinion on Drug Discovery
  78. History repeats itself: horse originated hyperimmune sera production against SARS CoV-2
    Ahu Pakdemirli, Elvin Çalişkan, Sabri Hacıoğlu, Erdem Danyer, Özlem KARDOĞAN, Züleyha ERGÜN KURT, Özcan YILDIRIM, Hakan TAŞKAYA, Bora ÜNDAR, Yasemin SEZGİN et al. · 2021 · TURKISH JOURNAL OF MEDICAL SCIENCES
  79. Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
    Kanako Terakawa, Daisuke Katagiri, Keiki Shimada, Lubna Sato, Hideki Takano · 2022 · CEN Case Reports
  80. Coronavirus Entry Inhibitors
    Qiaoshuai Lan, Shuai Xia, Lu Lu · 2022 · Advances in experimental medicine and biology
  81. Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease
    Raoul De Gasparo, Mattia Pedotti, Luca Simonelli, Petr Nickl, Frauke Muecksch, Irene Cassaniti, Elena Percivalle, Julio C. C. Lorenzi, Federica Mazzola, Davide Magrì et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  82. Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccine
    Alberto Grandi, Michele Tomasi, Irfan Ullah, Cinzia Bertelli, Teresa Vanzo, Silvia Accordini, Assunta Gagliardi, Ilaria Zanella, Mattia Benedet, Riccardo Corbellari et al. · 2023 · Research Square
  83. Fast end-to-end surface interpretation of SARS-CoV-2 variants by differentiable molecular surface interaction fingerprinting method
    Ziyang Zheng, Yanqi Jiao, Haixin You, Junfeng An, Yao Sun · 2023 · Computational and Structural Biotechnology Journal
  84. NSP6 regulates calcium overload-induced autophagic cell death and is regulated by KLHL22-mediated ubiquitination
    Xingyu Tao, Yanan Wang, Jiangbo Jin, Huilin Yan, Hui Yang, Xiaorui Wan, Ping Li, Yanghua Xiao, Qi Yu, Lingjiao Liu et al. · 2025 · Journal of Advanced Research
  85. The Impact of PET Imaging on Translational Medicine: Insights from Large-Animal Disease Models
    Zhengyan Deng, Peng Xi, Dongye Zheng, Zhaoheng Xie, Xiangxi Meng, Qiushi Ren · 2025 · Biomolecules
  86. A potential broad‐spectrum neutralizing antibody against Betacoronavirus
    Rong Wang, Jiazheng Guo, Jiansheng Lu, Peng Du, Jun Zhang, Yun‐Zhou Yu, Lei Chen, Zhiqi Xiong, Yuning Xiang, Xiaodan Ni et al. · 2023 · Journal of Medical Virology
  87. The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time
    C. Hendricks, C. Herd, M. Nel, G. Tintinger, M. Pepper · 2021 · Frontiers in Medicine
  88. SARS‐CoV‐2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?
    Marko Boskovic, William Migo, Robert Likić · 2021 · British Journal of Clinical Pharmacology
  89. A review on the COVID-19: Facts and current situation
    Urvashi Tiwari, Arjumand Bano, Mohammad Kalim Ahmad Khan · 2021 · NeuroPharmac Journal
  90. Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments
    César Piedra-Mora, Sally R. Robinson, Lisa H. Tostanoski, Denise Dayao, Abishek Chandrashekar, Katherine Bauer, Linda M. Wrijil, Sarah Ducat, Tammy Hayes, Jingyou Yu et al. · 2022 · Veterinary Pathology
  91. Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo
    Qianran Wang, Peng Lü, Yanqiu Nie, Yanni Shu, Huajun Zhang, Zidan Song, Yufeng Li, Hengrui Hu, Liushuai Li, Xi Wang et al. · 2022 · Virologica Sinica
  92. MIR 19® – world first specific antiviral drug for COVID-19 treatment: development and preclinical studies
    Musa Rakhimovich Khaitov, Alexandra A. Nikonova, Igor P. Shilovskiy, Ksenia V. Kozhikhova, И.А. Кофиади, Г.О. Гудима, L.I. Vishniakova, A.A. Nikolskii, V.I. Kovchina, Тимотиевич Екатерина Драгановна et al. · 2023 · Immunologiya
  93. A Mixture of Essential Oils from Three Cretan Aromatic Plants Inhibits SARS-CoV-2 Proliferation: A Proof-of-Concept Intervention Study in Ambulatory Patients
    Christos D Lionis, Elena Petelos, Manolis K. Linardakis, Athanasios Diamantakis, Emmanouil K. Symvoulakis, Maria-Nefeli Karkana, Marilena Kampa, Stergios Pirintsos, George Sourvinos, Elias Castanas · 2023 · Diseases
  94. CLINICAL MANAGEMENT OF PATIENTS WITH COVID-19. “LIVE” CLINICAL INSTRUCTION (2021)
    Садов’як Ірина Дмитрівна · 2021 · ДЕРЖАВНА НАУКОВА УСТАНОВА «НАУКОВО-ПРАКТИЧНИЙ ЦЕНТР ПРОФІЛАКТИЧНОЇ І КЛІНІЧНОЇ МЕДИЦИНИ» eBooks
  95. Convalescent plasma is of limited clinical benefit in critically ill patients with coronavirus disease-2019: a cohort study
    Li Huang, Che Zhang, Xihui Zhou, Zhou Zhao, Weiping Wang, Wei‐Dong Leng, Xiao Su, Qizhou Lian · 2021 · Journal of Translational Medicine
  96. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
    Rong Xiang, Yang Wang, Lili Wang, Xiaoqian Deng, Shanshan Huo, Shibo Jiang, Fei Yu · 2021 · Current Opinion in Virology
  97. Is SARS‐CoV‐2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody‐based therapeutics?
    Daniele Focosi, Massimo Franchini, Liise‐anne Pirofski, Fabrizio Maggi, Arturo Casadevall · 2021 · Reviews in Medical Virology
  98. Early Experience With Neutralizing Monoclonal Antibody Therapy For COVID-19
    Mark Paul Jarrett, Warren Licht, Kevin R. Bock, Zenobia J. Brown, Jamie S. Hirsch, Kevin Coppa, Rajdeep Brar, Steven Bello, Ira S. Nash · 2021 · medRxiv
  99. Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice
    Liat Bar‐On, Moshe Aftalion, Efi Makdasi, David Gur, Ron Alcalay, Hila Cohen, Adi Beth-Din, Ronit Rosenfeld, Hagit Achdout, Erez Bar‐Haim et al. · 2022 · Vaccines
  100. The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies
    Conrad En-Zuo Chan, Ching-Ging Ng, Angeline Pei-Chew Lim, Shirley G. K. Seah, De Hoe Chye, Steven K. K. Wong, Jie-Hui Lim, Vanessa Zi-Yun Lim, Soak-Kuan Lai, Pui-San Wong et al. · 2022 · Journal of Virology